지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 182 - 188 (7page)
이용수
초록· 키워드
오류제보하기
Purpose To investigate the impact of targeted treatment on direct medical costs of patients withadvanced non-small cell lung cancer (NSCLC).
Materials and MethodsMedical records of 108 stage IIIB/IV NSCLC patients treated in Seoul National UniversityHospital between 2003 and 2009, were reviewed to collect medical resources utilizationdata from the diagnosis of stage IIIB/IV NSCLC to the end of active anti-cancer treatment.
The direct medical costs were calculated by multiplying the number of medical resourcesused by the unit price. All costs were expressed in US dollars for each patient.
ResultsThe mean total direct medical costs were $34,732 (standard deviation, 21,168) in the studycohort. The mean total direct medical costs were higher in epidermal growth factor receptor(EGFR) mutation (EGFR MT)–positive patients than EGFR wild-type (EGFR WT) patients($41,403 vs. $30,146, p=0.005). However, the mean monthly direct medical costs did notdiffer significantly between EGFR MT–positive patients and EGFR WT patients ($2,120 vs.
$2,702, p=0.119) because of the longer duration of active anti-cancer treatment in EGFRMT–positive patients. This discrepancy was mainly attributable to EGFR MT–positivepatients’ lower non-chemotherapy costs ($948 vs. $1,522, p=0.007). The total and monthlydirect medical costs of ALK fusion–positive patients who did not receive ALK inhibitors didnot differ from WT/WT patients.
ConclusionThis study suggests that the availability of targeted agents for EGFR MT–positive patientslowers the mean monthly medical costs by prolonging survival and diminishing the use ofother medical resources, despite the considerable drug costs.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Bongers ML / 2012 / Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer : a systematic review / Pharmacoeconomics 30 : 17 ~ 34
Bouwes N. / / The cost of illness handbook / U.S. Environmental Protection Agency
Chouaid C / 2013 / Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospec
Cromwell I / 2012 / Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer : a real-world cost-effectiveness analysis / Lung Cance
Emanuel EJ / 2002 / Managed care, hospice use, site of death, and medical expenditures in the last year of life / Arch Intern Med 162 : 1722 ~ 1728
Bouwes N. / / The cost of illness handbook / U.S. Environmental Protection Agency
Chouaid C / 2013 / Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospec
Cromwell I / 2012 / Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer : a real-world cost-effectiveness analysis / Lung Cance
Emanuel EJ / 2002 / Managed care, hospice use, site of death, and medical expenditures in the last year of life / Arch Intern Med 162 : 1722 ~ 1728
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]
Journal of Pharmaceutical Investigation
2019 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
-
Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Overexpression of EGFR Protein in Bruneian Lung Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
Cancer Research and Treatment
2022 .04
-
Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0